For GLP-1 treatment in particular, employers “need to make sure the coverage is married with a patient engagement program, ...

Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...

Expanding access to cutting-edge diabetes and weight-loss drugs like Ozempic and Zepbound could prevent more than 42,000 ...

“Two major factors are driving this change,” said Alon Chen, Tastewise co-founder and chief executive officer. “First, the ...

Less than a week after the U.S. Food & Drug Administration (FDA) determined that the shortage of the tirzepatide injection, a glucagon-like peptide ...

The medicines regulator has urged GPs to be alert to signs of ‘misuse’ of GLP-1 receptor agonists for weight loss, such as ...

The GLP-1 RA semaglutide was associated with a 40%-70% reduced risk for first-time diagnosis of AD in patients with type 2 diabetes, real-world data show.

Hims & Hers (NYSE: HIMS) fell as much as 12% in trading on Wednesday after pharmaceutical company Novo Nordisk (NYSE: NVO) ...

Laks Pernenkil, Brian Feth, and Alex Philippidis go behind the headlines to discuss the impact of recent news, including ...

MGM Resorts plans to stop covering GLP-1 weight loss shots for its employees next year, after it faced constraints in what it ...

An analysis of over 400,000 patients with T1D revealed a rise in prescribing for glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors over the past decade.

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo ...